

Sherlock Biosciences Acquired by OraSure Technologies

Client News

December 19, 2024

Gunderson Dettmer represented client [Sherlock Biosciences](#), a global health company bringing next-generation diagnostics to consumers and healthcare providers, in its acquisition by OraSure Technologies, a leader in point-of-need and home diagnostic tests and sample management solutions.

This acquisition expands OraSure's innovation pipeline with the addition of Sherlock's molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specificity in a disposable format that is well-suited for over-the-counter usage. Sherlock's first molecular self-test is for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) which will expand OraSure's portfolio of rapid diagnostics for sexually transmitted infections (STIs), subject to regulatory approvals.

In the [announcement of the acquisition](#), OraSure President and CEO Carrie Eglinton Manner said, "The acquisition of Sherlock represents the next step in OTI's innovation strategy. Sherlock brings valuable capabilities with an advanced molecular platform that aims to deliver lab-like accuracy in a format that expands access to diagnostic insights through convenient, effortless tests. We are excited to welcome Sherlock's talented team to OTI and believe that Sherlock's unique capabilities will contribute significantly to the expansion of our pipeline of diagnostic tests in infectious disease, sexual health, and beyond."

The Gunderson Dettmer team was led by Tim Ehrlich and included Jim Hauser, Tim Kulis, Taylor Sarkaria, Sandra Lucero, Chris Sundquist, Joel Diamond, Tina Xu and Mark Macchi.

Companies

Sherlock Biosciences

OraSure Technologies

Related People

Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Jim Hauser

PARTNER

P +1 617 648 9146

Timothy J. Kulis

COUNSEL

P +1 617 648 9236

Taylor J. Sarkaria

ASSOCIATE

P +1 617 648 9317

Sandra Lucero

ASSOCIATE

P +1 617 648 9221

Chris Sundquist

ASSOCIATE

P +1 617 648 9329

Joel T. Diamond

ASSOCIATE

P +1 617 648 9136

T. Tina Xu

ASSOCIATE

P +1 212 430 3151

Mark Macchi

ASSOCIATE

P +1 617 648 9383

Related Services

Early-Stage Company

Life Sciences

Mergers & Acquisitions

Private & Public Companies

Featured Insights

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding

INSIGHTS

Legal 500 Country Comparative Guides 2025: Venture Capital (Singapore)